Research programme: IgE receptor therapeutic - Xenova
Alternative Names: IgE receptor therapeutic research programme - XenovaLatest Information Update: 29 Jul 2004
At a glance
- Originator Xenova Group
- Class
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Allergic asthma; Hypersensitivity
Most Recent Events
- 29 Jul 2004 Discontinued - Preclinical for Allergic asthma in United Kingdom (unspecified route)
- 29 Jul 2004 Discontinued - Preclinical for Allergy in United Kingdom (unspecified route)
- 28 Jun 2001 Cantab Pharmaceuticals has been acquired by Xenova Group